UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 164

Sortiert nach

Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis

Climacteric : the journal of the International Menopause Society, 2018-08, Vol.21 (4), p.341-345

Scarabin, P.-Y.

2018

Volltextzugriff (PDF)

Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis

Climacteric : the journal of the International Menopause Society, 2018-07, Vol.21 (4), p.341-345

Scarabin, P.-Y.

2018

Volltextzugriff (PDF)

Hormones and venous thromboembolism among postmenopausal women

Climacteric : the journal of the International Menopause Society, 2014-12, Vol.17 (S2), p.34-37

Scarabin, P.-Y.

2014

Volltextzugriff (PDF)

Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls

European journal of epidemiology, 2013-08, Vol.28 (8), p.621-647

2013

Volltextzugriff (PDF)

Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial

Arteriosclerosis, thrombosis, and vascular biology, 1997-11, Vol.17 (11), p.3071

1997

Volltextzugriff (PDF)

Effect of NFE2L2 Genetic Polymorphism on the Association Between Oral Estrogen Therapy and the Risk of Venous Thromboembolism in Postmenopausal Women

Clinical pharmacology and therapeutics, 2011-01, Vol.89 (1), p.60-64

2011

Volltextzugriff (PDF)

Hormone therapy and risk of venous thromboembolism among postmenopausal women

Climacteric : the journal of the International Menopause Society, 2009-01, Vol.12 (s1), p.76-80

2009

Volltextzugriff (PDF)

Indicators of lifetime endogenous estrogen exposure and risk of venous thromboembolism

Journal of thrombosis and haemostasis, 2006-01, Vol.4 (1), p.71-76

2006

Volltextzugriff (PDF)

Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives

Journal of thrombosis and haemostasis, 2004-09, Vol.2 (9), p.1594-1600

2004

Volltextzugriff (PDF)

The cardiovascular safety of oral alitretinoin: a population‐based cohort study involving 19 513 patients exposed to oral alitretinoin

British journal of dermatology (1951), 2021-10, Vol.185 (4), p.764-771

2021

Volltextzugriff (PDF)

VKORC1 genetic polymorphism and risk of venous thromboembolism in postmenopausal women: new findings and meta‐analysis

Journal of thrombosis and haemostasis, 2009-06, Vol.7 (6), p.1034-1036

2009

Volltextzugriff (PDF)

Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study

Journal of thrombosis and haemostasis, 2006-06, Vol.4 (6), p.1259-1265

2006

Volltextzugriff (PDF)

Elevated plasma fibrin D‐dimer as a risk factor for vascular dementia: the Three‐City cohort study

Journal of thrombosis and haemostasis, 2009-12, Vol.7 (12), p.1972-1978

2009

Volltextzugriff (PDF)

L'hormonothérapie substitutive de la ménopause apporte-t-elle un bénéfice cardiovasculaire ?

La revue de medecine interne, 2003-04, Vol.24 (4), p.216-217

Scarabin, P.-Y

2003

Volltextzugriff (PDF)

Diagnostic accuracy of compression ultrasonography for the detection of asymptomatic deep venous thrombosis in medical patients--the TADEUS project

Thrombosis and haemostasis, 2001-08, Vol.86 (2), p.529

2001

Volltextzugriff (PDF)

Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial

Arteriosclerosis, thrombosis, and vascular biology, 2003-09, Vol.23 (9), p.1671

2003

Volltextzugriff (PDF)

Hormone replacement therapy and circulating ICAM-1 in postmenopausal women--a randomised controlled trial

Thrombosis and haemostasis, 1999-05, Vol.81 (5), p.673

1999

Volltextzugriff (PDF)

Risque cardiovasculaire associé à l’alitrétinoïne. Analyse de la population française par la base SNDS-SNIIRAM

Annales de dermatologie et de vénéréologie, 2019-12, Vol.146 (12), p.A50-A50

2019

Volltextzugriff (PDF)

Assessment of the risk for venous thromboembolism among users of hormone replacement therapy

Drugs & aging, 1999, Vol.14 (1), p.55-61

1999

Volltextzugriff (PDF)

Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk and the ECTIM study

Atherosclerosis, 1996-01, Vol.119 (1), p.119-127

1996

Volltextzugriff (PDF)

CAN WE AVOID VENOUS THROMBOEMBOLISM RISK WITH HORMONE THERAPY?

Maturitas, 2009, Vol.63, p.S11-S12

Scarabin, P.-Y

2009

Volltextzugriff (PDF)

Population correlates of coagulation factor VII. Importance of age, sex, and menopausal status as determinants of activated factor VII

Arteriosclerosis, thrombosis, and vascular biology, 1996-09, Vol.16 (9), p.1170

1996

Volltextzugriff (PDF)

Traitement hormonal substitutif de la ménopause et risques cardiovasculaires

La Revue de médecine interne (Paris), 2000, Vol.21, p.475-477

Scarabin, P.Y.

2000

Volltextzugriff (PDF)

The effects of transdermal and oral estrogen/progesterone regimens on free and total protein S in postmenopausal women

Thrombosis and haemostasis, 2001-08, Vol.86 (2), p.713

2001

Volltextzugriff (PDF)

Haemostatic variables and menopausal status: influence of hormone replacement therapy

Thrombosis and haemostasis, 1993, Vol.70 (4), p.584

1993

Volltextzugriff (PDF)

1 – 25 von 164

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(128)
Mit Volltextzugriff
(105)

Publikationsform

Artikel
(162)
Tagungsberichte
(2)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis

Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis

Hormones and venous thromboembolism among postmenopausal women

Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls

Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial

Effect of NFE2L2 Genetic Polymorphism on the Association Between Oral Estrogen Therapy and the Risk of Venous Thromboembolism in Postmenopausal Women

Hormone therapy and risk of venous thromboembolism among postmenopausal women

Indicators of lifetime endogenous estrogen exposure and risk of venous thromboembolism

Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives

The cardiovascular safety of oral alitretinoin: a population‐based cohort study involving 19 513 patients exposed to oral alitretinoin

VKORC1 genetic polymorphism and risk of venous thromboembolism in postmenopausal women: new findings and meta‐analysis

Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study

Elevated plasma fibrin D‐dimer as a risk factor for vascular dementia: the Three‐City cohort study

L'hormonothérapie substitutive de la ménopause apporte-t-elle un bénéfice cardiovasculaire ?

Diagnostic accuracy of compression ultrasonography for the detection of asymptomatic deep venous thrombosis in medical patients--the TADEUS project

Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial

Hormone replacement therapy and circulating ICAM-1 in postmenopausal women--a randomised controlled trial

Risque cardiovasculaire associé à l’alitrétinoïne. Analyse de la population française par la base SNDS-SNIIRAM

Assessment of the risk for venous thromboembolism among users of hormone replacement therapy

Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk and the ECTIM study

CAN WE AVOID VENOUS THROMBOEMBOLISM RISK WITH HORMONE THERAPY?

Population correlates of coagulation factor VII. Importance of age, sex, and menopausal status as determinants of activated factor VII

Traitement hormonal substitutif de la ménopause et risques cardiovasculaires

The effects of transdermal and oral estrogen/progesterone regimens on free and total protein S in postmenopausal women

Haemostatic variables and menopausal status: influence of hormone replacement therapy

Suchergebnisse filtern